Literature DB >> 15228387

Binding of salivary agglutinin to IgA.

Antoon J M Ligtenberg1, Floris J Bikker, Jolanda M A De Blieck-Hogervorst, Enno C I Veerman, Arie V Nieuw Amerongen.   

Abstract

SAG (salivary agglutinin), which is identical to gp-340 (glycoprotein-340) from the lung, is encoded by DMBT1 (deleted in malignant brain tumours 1). It is a member of the SRCR (scavenger receptor cysteine-rich) superfamily and contains 14 SRCR domains, 13 of which are highly similar. SAG in saliva is partially complexed with IgA, which may be necessary for bacterial binding. The goal of the present study was to characterize the binding of purified SAG to IgA. SAG binds to a variety of proteins, including serum and secretory IgA, alkaline phosphatase-conjugated IgGs originating from rabbit, goat, swine and mouse, and lactoferrin and albumin. Binding of IgA to SAG is calcium dependent and is inhibited by 0.5 M KCl, suggesting that electrostatic interactions are involved. Binding of IgA was destroyed after reduction of SAG, suggesting that the protein moiety is involved in binding. To pinpoint further the binding domain for IgA on SAG, a number of consensus-based peptides of the SRCR domains and SRCR interspersed domains were designed and synthesized. ELISA binding studies with IgA indicated that only one of the peptides tested, comprising amino acids 18-33 (QGRVEVLYRGSWGTVC) of the 109-amino-acid SRCR domain, exhibited binding to IgA. This domain is identical to the domain of SAG that is involved in binding to bacteria. Despite this similar binding site, IgA did not inhibit binding of Streptococcus mutans to SAG or peptide. These results show that the binding of IgA to SAG is specifically mediated by a peptide sequence on the SRCR domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228387      PMCID: PMC1134054          DOI: 10.1042/BJ20040265

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Identification of a nonmucin glycoprotein (gp-340) from a purified respiratory mucin preparation: evidence for an association involving the MUC5B mucin.

Authors:  D J Thornton; J R Davies; S Kirkham; A Gautrey; N Khan; P S Richardson; J K Sheehan
Journal:  Glycobiology       Date:  2001-11       Impact factor: 4.313

2.  Immunochemical analysis of high molecular-weight human salivary mucins (MG1) using monoclonal antibodies.

Authors:  E C Veerman; M Valentijn-Benz; P A van den Keybus; W M Rathman; J K Sheehan; A V Nieuw Amerongen
Journal:  Arch Oral Biol       Date:  1991       Impact factor: 2.633

3.  Differential distribution of salivary agglutinin and amylase in the Golgi apparatus and secretory granules of human salivary gland acinar cells.

Authors:  K Takano; M Bogert; D Malamud; E Lally; A R Hand
Journal:  Anat Rec       Date:  1991-07

4.  Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120.

Authors:  Zhiwei Wu; Donald Van Ryk; Cheryl Davis; William R Abrams; Irwin Chaiken; John Magnani; Daniel Malamud
Journal:  AIDS Res Hum Retroviruses       Date:  2003-03       Impact factor: 2.205

5.  Differentiation and interaction of secretory immunoglobulin A and a calcium-dependent parotid agglutinin for several bacterial strains.

Authors:  J Rundegren; R R Arnold
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

6.  Adherence of mutans streptococci to other oral bacteria.

Authors:  R J Lamont; B Rosan
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans.

Authors:  T Ericson; J Rundegren
Journal:  Eur J Biochem       Date:  1983-06-15

8.  Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses.

Authors:  Kevan L Hartshorn; Mitchell R White; Tirsit Mogues; Toon Ligtenberg; Erika Crouch; Uffe Holmskov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-07-18       Impact factor: 5.464

9.  High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.

Authors:  R J Boackle; M H Connor; J Vesely
Journal:  Mol Immunol       Date:  1993-02       Impact factor: 4.407

10.  Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily.

Authors:  Floris J Bikker; Antoon J M Ligtenberg; Kamran Nazmi; Enno C I Veerman; Wim van't Hof; Jan G M Bolscher; Annemarie Poustka; Arie V Nieuw Amerongen; Jan Mollenhauer
Journal:  J Biol Chem       Date:  2002-06-05       Impact factor: 5.157

View more
  16 in total

1.  Functions of cell surface-anchored antigen I/II family and Hsa polypeptides in interactions of Streptococcus gordonii with host receptors.

Authors:  Nicholas S Jakubovics; Steven W Kerrigan; Angela H Nobbs; Nicklas Strömberg; Craig J van Dolleweerd; Dermot M Cox; Charles G Kelly; Howard F Jenkinson
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Variant size- and glycoforms of the scavenger receptor cysteine-rich protein gp-340 with differential bacterial aggregation.

Authors:  Christer Eriksson; Lars Frängsmyr; Liza Danielsson Niemi; Vuokko Loimaranta; Ulf Holmskov; Tomas Bergman; Hakon Leffler; Howard F Jenkinson; Nicklas Strömberg
Journal:  Glycoconj J       Date:  2007-01-23       Impact factor: 2.916

3.  The effect of phytosphingosine associated with tooth brushing on color change, surface roughness, and microhardness of dental enamel - an in vitro and in situ study.

Authors:  Carolina Noronha Ferraz de Arruda; Rocio Geng Vivanco; Ayodele Alves Amorim; Adriana Cavalcanti Ferreira; Rafaella Tonani-Torrieri; Floris Jacob Bikker; Fernanda de Carvalho Panzeri Pires-de-Souza
Journal:  Clin Oral Investig       Date:  2022-07-13       Impact factor: 3.606

4.  Respiratory Deleted in Malignant Brain Tumours 1 (DMBT1) levels increase during lung maturation and infection.

Authors:  H Müller; C End; C Weiss; M Renner; A Bhandiwad; B M Helmke; N Gassler; M Hafner; A Poustka; J Mollenhauer; J Poeschl
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

5.  Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system.

Authors:  Robert C De Lisle; Weihong Xu; Bruce A Roe; Donna Ziemer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-17       Impact factor: 4.052

6.  Multiple components contribute to ability of saliva to inhibit influenza viruses.

Authors:  M R White; E J Helmerhorst; A Ligtenberg; M Karpel; T Tecle; W L Siqueira; F G Oppenheim; K L Hartshorn
Journal:  Oral Microbiol Immunol       Date:  2009-02

Review 7.  Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.

Authors:  Antoon J M Ligtenberg; Niclas G Karlsson; Enno C I Veerman
Journal:  Int J Mol Sci       Date:  2010-12-17       Impact factor: 5.923

8.  Streptococcus pyogenes antigen I/II-family polypeptide AspA shows differential ligand-binding properties and mediates biofilm formation.

Authors:  Sarah E Maddocks; Christopher J Wright; Angela H Nobbs; Jane L Brittan; Linda Franklin; Nicklas Strömberg; Aras Kadioglu; Mark A Jepson; Howard F Jenkinson
Journal:  Mol Microbiol       Date:  2011-07-15       Impact factor: 3.501

9.  Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactant.

Authors:  Hanna Müller; Caroline End; Marcus Renner; Burkhard M Helmke; Nikolaus Gassler; Christel Weiss; Dominik Hartl; Matthias Griese; Mathias Hafner; Annemarie Poustka; Jan Mollenhauer; Johannes Poeschl
Journal:  Respir Res       Date:  2007-10-01

10.  Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries.

Authors:  Anette Jonasson; Christer Eriksson; Howard F Jenkinson; Carina Källestål; Ingegerd Johansson; Nicklas Strömberg
Journal:  BMC Infect Dis       Date:  2007-06-11       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.